{"title": "PDF", "author": "PDF", "url": "https://biomedicalsciences.unimelb.edu.au/__data/assets/pdf_file/0020/1761221/67KelleherAIDS06.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Copyright \u00a9 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.2.Connor EM, Sperling zidovudi ne treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. NEngl percutane ousexposure. Centers forDisease Control and Prevention Needles design ofavaccine -HIV-Bisreportedelsewhere Vol20No2Copyright \u00a9 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.Researc hLetters 295 250 200 150 100 50 0 0 2 4 6 8 10 12 1450 100 150 Time (w eeks)SFU/10 6 cells 4 0 2 4 6 8 10 12 143 2 1 0 1 2 3 4 5Stimulation Inde x (SI) 0.2 0.18 0.16 0.14 0.12 0.1 0.06 0.04 0.02 0 0.02% CD4+ T cells% CD8+ T cells1.4 1.2 0.8 0.6 0.4 0.2 0 0.21 0 8 9 12 0 8 9 120.18 0.16 0.14 0.12 0.1 0.08 0.06 0.04 0.02 0 0.02 0.18 0.16 0.14 0.12 0.1 0.08 0.06 0.04 0.02 0 0.02 Weeks of tr ialTime (w eeks) INF- IL-2(a) (b) is prohibited.theIFN- genzyme-link edimmunospot assay(ELIspot) response per schedule allspecied visits. peptides with (SD) time Fowlpo anapproach 2006, Vol20No2Copyright \u00a9 Lippincott Wilkins. Unauthorized reproduction of this article is prohibited.4.Pantale oG,Koup RA. Correlates ofimmune protection in HIV-1 infection: vaccine regimen priming "}